Bafna Pharmaceuticals share price & results

Bafna Pharmaceuticals Limited· Healthcare

Results to: Jun 2026
Ownership as of: Sept 2026

Chennai-based, export-led manufacturer of non-betalactum solid oral dosage forms (tablets, capsules) for regulated and emerging pharma markets, also acting as a Contract Manufacturing Organization (CMO/CRAMS partner).

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

Metric	Value	Change	Basis	Period	Note
Revenue	26.6 ₹ crore	−23.2% YoY	Quarterly, as filed	Quarter to Jun 2026	Revenue from operations as filed.
Operating margin	3.4 %	−11.3 pts YoY	Operating profit / revenue	Quarter to Jun 2026	For the quarter; a change is in percentage points.
Net profit	0.08 ₹ crore	−97.6% YoY	Quarterly, as filed	Quarter to Jun 2026	Profit after tax as filed.
Return on equity	Unavailable	+67.3 ptsFY Mar 2020 vs FY Mar 2019	Trailing twelve months	TTM · period unavailable	Not in the analysed materials. No older figure is substituted.
Free cash flow margin	Unavailable	−90.3 ptsFY Mar 2020 vs FY Mar 2019	Fiscal year	FY · period unavailable	Not in the analysed materials. No older figure is substituted.
Revenue growth (YoY)	Unavailable	−0.2 ptsFY Mar 2020 vs FY Mar 2019	Trailing twelve months	TTM · period unavailable	Not in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Price

₹442.75 +1.99% · +₹8.65

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +227.0% 1Y

1Y: ₹135.41 on 24 Oct 2025 → ₹442.75. High ₹470.55 (19 Oct 2026), low ₹99.16 (13 Mar 2026).

Previous close: ₹434.1
Market cap: ₹1.0k Cr
52-week range: ₹99.16 – ₹470.55
One year: +233.65%

Overview

Symbol: NSE:BAFNAPH
Sector: Healthcare
Exchange: NSE
Currency: INR

What Bafna Pharmaceuticals Limited does

Based on the company's own presentations, annual report and earnings calls.

Bafna Pharmaceuticals manufactures generic pharmaceutical formulations (mainly tablets and capsules) at its UK-MHRA, TGA-Australia and EU/WHO-GMP certified facility in Chennai, and sells them under its own brands as well as on a contract basis for other pharma companies. It exports over 70% of its output across roughly 21 countries spanning the UK, Europe, Australia, Africa, CIS and South-East Asia. Beyond finished-dose manufacturing, it offers Contract Research & Manufacturing (CRAMS), technology transfer, and formulation and analytical development services, backed by an in-house DSIR-approved R&D centre that prepares regulatory dossiers for new market launches.

Segments

Own-brand generics
Contract Manufacturing (CMO/CRAMS)
R&D / technology-transfer services

Manufacturing facilities: 2 units in Chennai (Madhavaram Unit-I; Grantlyon/Redhills Unit-II)
Installed capacity - Tablets: ~900 million units/year (~65% utilization in FY25)
Installed capacity - Capsules: ~375 million units/year (~80% utilization in FY25)
Packaging lines capacity: ~1,000 million units/year across 4 blister + 1 bottle line (~90% utilization in FY25)
Employees: 600+
Export markets: 21 countries across UK, Europe, Australia, Africa, CIS and SE Asia

Founded 1995Headquarters Chennai, Tamil Nadu, IndiaEmployees 600 (FY25) Company website

Fundamentals

Ratios, each with its period

Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2015 to Mar 2020).

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
335.00 days 292.00 days 303.00 days 195.00 days 208.00 days 52.00 days

How it is calculated. Reported receivable days from the annual accounts.
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
72.00 days 90.00 days 118.00 days 102.00 days 122.00 days 208.00 days

How it is calculated. Reported inventory days, using material cost / cost of goods sold.
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
189.00 days 208.00 days 168.00 days 273.00 days 519.00 days 229.00 days

How it is calculated. Reported payable days, using material cost / cost of goods sold.
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
218.00 days 174.00 days 253.00 days 24.00 days -190.00 days 31.00 days

How it is calculated. Reported debtor days plus inventory days less payable days.
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
50.00 days 106.00 days -39.00 days -113.00 days -210.00 days 90.00 days

How it is calculated. Reported net working capital days from the annual accounts.
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

How it is calculated. Reported dividend payout as a percentage of annual profit.
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
— — — — — —

How it is calculated. Market capitalisation from the current stock record.

Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020
335.00 days	292.00 days	303.00 days	195.00 days	208.00 days	52.00 days

Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020
72.00 days	90.00 days	118.00 days	102.00 days	122.00 days	208.00 days

Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020
189.00 days	208.00 days	168.00 days	273.00 days	519.00 days	229.00 days

Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020
218.00 days	174.00 days	253.00 days	24.00 days	-190.00 days	31.00 days

Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020
50.00 days	106.00 days	-39.00 days	-113.00 days	-210.00 days	90.00 days

Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020
0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020
—	—	—	—	—	—

A dash means inputs are missing or too old, the ratio does not apply, or the value is outside the supported range. FY uses the reported fiscal period; TTM the latest twelve months; valuations use the current market cap with the chosen earnings period. Screen Indian stocks on these ratios →

Financials

What the filings say

Net profit, year on year: −98% (quarter to jun 2026 against jun 2025).

In ₹ crore. Oldest period first.

Line item	Sept 2024	Dec 2024	Mar 2025	Jun 2025	Sept 2025	Dec 2025	Mar 2026	Jun 2026
Sales	40	33	39	35	35	38	42	27
Expenses	37	30	36	30	31	35	39	26
Operating profit	4	3	3	5	4	3	4	1
Operating margin	9.4%	9.2%	8.0%	14.6%	12.1%	8.0%	8.4%	3.4%
Other income	1	0	-1	1	1	1	2	2
Interest	1	1	1	1	1	1	1	1
Depreciation	2	2	0	1	1	2	2	2
Profit before tax	3	1	1	3	3	2	3	0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	−5.0%	0.0%
Net profit	3	1	1	3	3	2	3	0
EPS (₹ per share)	1.11	0.40	0.55	1.43	1.32	0.78	1.16	0.03

Source: Inve data · income statement, quarterly · to Jun 2026

In ₹ crore. Oldest period first.

Line item	Mar 2024	Mar 2025	Mar 2026
Sales	152	146	151
Expenses	141	135	135
Operating profit	11	11	16
Other income	4	1	5
Interest	2	3	4
Depreciation	5	5	6
Profit before tax	7	4	11
Net profit	7	4	11

Source: Inve data · income statement, annual · to Mar 2026

In ₹ crore. Oldest period first.

Line item	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	24	24	24	24	24	24
Reserves	33	38	50	57	61	72
Borrowings	15	11	23	24	28	37
Other liabilities	14	17	33	42	40	42
Total liabilities	86	90	130	148	153	176
Fixed assets	36	39	40	40	59	82
Capital work in progress	1	0	2	12	7	3
Investments	0	0	0	0	0	0
Other assets	50	51	88	95	87	91
Total assets	86	90	130	148	153	176

Source: Inve data · balance sheet · to Mar 2026

In ₹ crore. Oldest period first.

Line item	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020
Cash from operations	9	-3	14	-7	-1	-34
Cash from investing	56	-1	-8	38	4	33
Cash from financing	-66	4	-5	-31	-2	7
Net cash flow	0	0	0	0	0	6
Free cash flow	2	-5	20	40	-1	-36

Source: Inve data · cash flow · to Mar 2020

In days and %. Oldest period first.

Line item	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	49	63	130	109	101	106
Inventory days	154	185	129	125	127	129
Days payable	107	113	165	149	140	139
Cash conversion cycle	96	135	94	84	88	96
Working capital days	121	123	104	92	74	74
Return on capital employed	10.0%	11.0%	16.0%	9.0%	8.0%	12.0%
Dividend payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: Inve data · annual ratios · to Mar 2026

Ownership

Who owns it

Promoters hold 75.00% as of Sept 2026; institutions added 0.00 pts since Jun 2026.

Promoters 0.00 pts 75.00%
Foreign institutions 0.00 pts 9.34%
Domestic institutions 0.00 pts 0.00%
Public 0.00 pts 15.66%

6,810 shareholders on the register.

Source: Exchange shareholding filings · to Sept 2026 · 8 filings held

Who was buying across the market this quarter

Who bought this quarter

since Jun 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

newly disclosed 3.21% held

The same filing shows 0 holders trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Sep 2026 filing

Every holder of Bafna Pharmaceuticals Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.

Holder	Stake	Change
	74.57%	unchanged
	3.21%	newly disclosed
FPI fund	3.12%	unchanged
FPI fund	3.01%	unchanged
	2.73%	unchanged
	1.35%	unchanged
	1.29%	unchanged
	0.21%	unchanged
	0.18%	unchanged
	0.03%	unchanged
	0.01%	unchanged
	0.01%	unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Your own record

Start an Inve Case for Bafna Pharmaceuticals Limited

Free account: one company. Everything above stays public.

Write why you follow Bafna Pharmaceuticals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Bafna Pharmaceuticals Limited

Guides on how to read this kind of business and the numbers that matter.